Inhibitors of histone methyltransferases and demethylases such as EZH2, KDM5A, and LSD1 have shown the ability to reprogram drug-tolerant states or impair survival of dormant cancer cells, with several agents (e.g., tazemetostat, CPI-455, ORY-1001, GSK2879552) already in preclinical development or early-phase clinical evaluation [137,138,139]. The gene discussed is EZH2; the disease is cancer.